Andrade Juliana Alves Manhães de, Meinerz Gisele, Palma Raphael, Rech Eduardo, Dall'Agnese Marco Antônio Vinciprova, Bundchen Cristiane, Nunes Fernanda Bordignon, Branchini Gisele, Keitel Elizete
Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil.
Universidade Federal de Ciências da Saúde de Porto Alegre, Programa de Pós-Graduação em Patologia, Porto Alegre, RS, Brazil.
J Bras Nefrol. 2025 Jan-Mar;47(1):e20240107. doi: 10.1590/2175-8239-JBN-2024-0107en.
Acute kidney injury (AKI) in the setting of COVID-19 is associated with worse clinical and renal outcomes, with limited long-term data.
To evaluate critically ill COVID-19 patients with AKI that required nephrologist consultation (NC-AKI) in a tertiary hospital.
Prospective single-center cohort of critically ill COVID-19 adult patients with NC-AKI from May 1st, 2020, to April 30th, 2021. Kidney replacement therapy (KRT), recovery of kidney function, and death at 90-day and 1-year follow-up were evaluated.
360 patients were included, 60.6% were male, median age was 66.0 (57.0-72.0) years, 38.1% had diabetes, and 68.6% had hypertension. AKI stages 1, 2, and 3 were detected in 3.6%, 5.6%, and 90.8% of patients, respectively. KRT was indicated in 90% of patients. At the 90-day follow-up, 88.1% of patients died and 10.0% had recovered kidney function. Female gender (p = 0.047), older age (p = 0.047), AKI stage 3 (p = 0.005), requirement of KRT (p < 0.0001), mechanical ventilation (p < 0.0001), and superimposed bacterial infection (p < 0.0001) were significantly associated death within 90 days. At 1 year, mortality was 89.3%. Amongst surviving patients, 72% recovered kidney function, although with significantly lower eGFR compared to baseline (85.5 ± 23.6 vs. 65.9 ± 24.8 mL/min, p = 0.003).
Critically ill COVID-19 patients with NC-AKI presented a high frequency of AKI stage 3 and KRT requirement, with a high 90-day mortality. Surviving patients had high rates of recovery of kidney function, with a lower eGFR at one-year follow-up compared to baseline.
新型冠状病毒肺炎(COVID-19)背景下的急性肾损伤(AKI)与更差的临床和肾脏预后相关,长期数据有限。
评估在一家三级医院中需要肾病专家会诊的COVID-19重症患者(NC-AKI)。
对2020年5月1日至2021年4月30日期间患有NC-AKI的COVID-19成年重症患者进行前瞻性单中心队列研究。评估肾脏替代治疗(KRT)、肾功能恢复情况以及90天和1年随访时的死亡情况。
纳入360例患者,60.6%为男性,中位年龄为66.0(57.0 - 72.0)岁,38.1%患有糖尿病,68.6%患有高血压。分别有3.6%、5.6%和90.8%的患者检测到AKI 1期、2期和3期。90%的患者需要进行KRT。在90天随访时,88.1%的患者死亡,10.0%的患者肾功能恢复。女性(p = 0.047)、年龄较大(p = 0.047)、AKI 3期(p = 0.005)、需要KRT(p < 0.0001)、机械通气(p < 0.0001)以及合并细菌感染(p < 0.0001)与90天内死亡显著相关。1年时,死亡率为89.3%。在存活患者中,72%肾功能恢复,尽管与基线相比估算肾小球滤过率(eGFR)显著降低(85.5 ± 23.6 vs. 65.9 ± 24.8 mL/min,p = 0.003)。
患有NC-AKI的COVID-19重症患者AKI 3期和需要KRT的频率较高,90天死亡率较高。存活患者肾功能恢复率较高,但1年随访时的eGFR较基线更低。